Drug General Information |
Drug ID |
D0N3LY
|
Former ID |
DNC000463
|
Drug Name |
Conantokins T
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Target and Pathway |
Target(s) |
Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Antagonist |
[1]
|
KEGG Pathway
|
Ras signaling pathway
|
Rap1 signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Circadian entrainment
|
Long-term potentiation
|
Glutamatergic synapse
|
Dopaminergic synapse
|
Alzheimer's disease
|
Amyotrophic lateral sclerosis (ALS)
|
Huntington's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Nicotine addiction
|
Alcoholism
|
Systemic lupus erythematosus
|
PANTHER Pathway
|
Huntington disease
|
Ionotropic glutamate receptor pathway
|
Metabotropic glutamate receptor group III pathway
|
Metabotropic glutamate receptor group I pathway
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
Pathway Interaction Database
|
ErbB4 signaling events
|
Reelin signaling pathway
|
Reactome
|
EPHB-mediated forward signaling
|
Unblocking of NMDA receptor, glutamate binding and activation
|
CREB phosphorylation through the activation of CaMKII
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
RAF/MAP kinase cascade
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
BDNF signaling pathway
|
References |
REF 1 | Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16. |